Greencross Limited (GXL) – NEUTRAL
|Date of Report||ASX||Price||Price Target||Analyst Recommendation|
|Date of Report|
|Sector : Consumer Discretionary||52-Week Range: A$3.84 – 6.56|
|Industry: Specialty Retail||Market Cap: A$478.1m|
We rate GXL as a Neutral for the following reasons:
- Significant network around Australia, with a well-known brand name – ~247 stores.
- Increased focused on integrated locations – vet clinics and retail shop combined should increase GXL’s share of wallet.
- Increased education and pet ownership should continue to drive demand for veterinary services – Australia has one of the highest global pet ownership rates.
- New CEO has reset market estimates and Company strategy, which could yield improved top line and earnings growth for the Company.
- Bigger focus on data analytics and increasing engagement from GXL’s 1.8 million active users.
- Potential corporate activity – recent transactions have traded at attractive multiples. International player PetCo currently owns ~3% of GXL.
- Industry is expected to grow between 2-3% per annum.
- Expansion into overseas markets could provide a step change in earnings profile.
We see the following key risks to our investment thesis:
- Changing living preferences – more families are renting (restrictions around keeping pets) and living in high-rise buildings.
- Increased competitive pressures, particularly if Amazon launch a pet food/care service as they have done in the US.
- Significant decline in pet ownership.
- Recession in Australia – leading to reduced disposable income.
- Execution risk with opening 20 stores p.a.
- Value destructive acquisition.
GXL’s FY18 results were mostly in line or slightly ahead of expectations, with underlying EBITDA $97.6m a touch below estimates of $98.6 (but in line with our estimates), underlying NPAT of $37.2m ahead of estimates of $37.0m and EPS of 31.5cps was slightly ahead of consensus estimates of 31.4cps.
Further management noted that sales momentum has carried into FY19, with group revenue up +8% and like-for-like sales growth up +5.8%. We are cognisant of the trading pressures GXL faces from competition, however we are encouraged by the new management’s approach to balance sheet and earnings growth.
We continue to see merit in GXL’s integrated store strategy (retail + vet clinic) as a sensible long-term strategy. This should provide the Company a competitive advantage in what is a tough retail environment.
Further, the opportunity is significant to leverage off the 1.8 million active users, although execution risk remains. We maintain our Neutral recommendation.
- Focus on increasing existing spend from active users. Within this 1.8m active users, there are 60,000 HPP (Healthy Pets Plus) members who pay at annual fee of $440 p.a. The balance are members of the lift program in Australia and New Zealand. All customers average spends (not just loyalty customers) around $270 p.a. (for just retail) and visits the company stores average 5 times are year; on solely vet services, on average they spend $630 p.a. and visit around 4 times are year. Loyalty customers spend more than this on average. However, if the customers using retail and vet, then the average visits are 10-12 times per year, spending on average ~$360 on retail and ~$770 on vet services. Clearly if the customer is using both services at GXL, then they are more engaged versus individual services. Further, customers using retail, vet and grooming is spending around ~$1,450 p.a. and visiting 15 times are year. The key goal is to improve the people across the spectrum (from retail or vet -> retail & vet / retail, vet & grooming) to get an increase wallet of share.
- Operating cost savings on target. The Company is looking to remove from its cost base in order of $10-13m in operating cost p.a. However, as we have previously noted we would caution against assuming that all of the $10-13m will drop to the bottom line, as the Company is likely to reinvest some in price and growth initiatives. Management on the analysts’ conference call noted that they plan to reinvest $3-5m of this cost savings into the business.
- FY18 revenue. Group delivered solid top line growth of +7.5% in FY18, with like-for-like sales growth of +4.9%. Management noted this momentum has continued into FY19 with year-to-date group like-for-like sales growth up +5.8%. Further, GXL’s integrated sites, retail stores with in-store clinics and other services, are delivering like-for-like sales growth of +8.5%. The group now has 54 integrated sites comprising retail stores with an in-store clinic.
- FY18 operating earnings (EBITDA). Despite solid top line growth, group EBITDA was down -6.5% on pcp, driven by -16.9% decline in Australian Vet earnings and +53.1% increase in corporate costs. Cost of doing business (CODB) as a percentage of revenue was higher across all segments, particularly Australian Vet due to the earnings pressure. Group operating costs were up +9.5% over the year.
FY18 RESULTS SUMMARY…
FY18 P&L compared to the prior year are presented in the table below.
Figure 1: GXL FY18 P&L summary
Source: Company, BTIG estimates
Key points from the results release:
- Revenue. Group delivered solid top line growth of +7.5% in FY18, with like-for-like sales growth of +4.9%. Management noted this momentum has continued into FY19 with year-to-date group like-for-like sales growth up +5.8%. Further, GXL’s integrated sites, retail stores with in-store clinics and other services, are delivering like-for-like sales growth of +8.5%. The group now has 54 integrated sites comprising retail stores with an in-store clinic.
- Operating earnings (EBITDA). Despite solid top line growth, group EBITDA was down -6.5% on pcp, driven by -16.9% decline in Australian Vet earnings and +53.1% increase in corporate costs. Cost of doing business (CODB) as a percentage of revenue was higher across all segments, particularly Australian Vet due to the earnings pressure. Group operating costs were up +9.5% over the year.
- Australian Retail. Australian Retail underlying earnings growth was driven by +5.1% like-for-like sales growth, which was on the back of +3.1% growth in like-for-like transactions and increased basket size. Australian Retail gross margin also improved by 70bps to 47.9% due to higher promotional effectiveness and increased sales of private labels (company owned brands) products.
- Australian Vet. GXL reported +12.3% top line growth in Australian veterinary division, driven by the rollout of in-store clinics, clinic acquisitions and specialty and emergency acquisitions. Like-for-like sales were up +4.3%. However, whilst strong like-for-like sales growth in specialty hospitals and in-store clinics was a feature, like-for-like sales in stand-alone GP clinics declined by -2.2% on the back of lower visit numbers. Management noted that like-for-like sales in stand-alone clinics have now stabilized.
- Cash flow. Cash flow was solid over the year, with the Company achieving 101% EBITDA cash conversion, driven by favorable working capital movements.
- FY19 outlook. GXL has seen the solid top line growth in FY18 continue into FY19, with group like-for-like sales growth of +5.8% in the first 6 weeks of trading. Retail business has continued its strong sales momentum with like-for-like sales up +6.1%. Australian Vet like-for-like sales growth is up +5.2% year-to-date and like-for-like sales in stand-alone GP clinics have stabilized. As a consequence of the above, group revenue is up +8% in the first 6 weeks of FY19.
Significant opportunity in GXL’s active users…
Within this 1.8m active users, there are 60,000 HPP (Healthy Pets Plus) members who pay an annual fee of $440 p.a. The balance are members of the lift program in Australia and New Zealand. All customers average spends (not just loyalty customers), on average $270 p.a. (for just retail) and visits the company stores on average, 5 times are year; on solely vet services, on average they spend $630 p.a. and visit around 4 times are year. Loyalty customers spend more than this on average. However, if the customers using retail and vet, then the average visits are 10-12 times per year, spending on average ~$360 on retail and ~$770 on vet services. Clearly if the customer is using both services at GXL, then they are more engaged versus individual services. Further, customers using retail, vet and grooming is spending around ~$1,450 p.a. and visiting 15 times are year. The key goal is to improve the people across the spectrum (from retail or vet -> retail & vet / retail, vet & grooming) to get an increase wallet of share.
Management believes at the moment most of their clients are still using just retail services and there is a lot of scope to move up the wallet share. This is in part due to the company still rolling out services (medical and non-medical) in-store for customer convenience. There are currently 247 stores and only 54 in-store clinics, i.e. ~22% penetration. This needs to be higher in order to achieve higher wallet share. Grooming salons penetration is currently around 106 and needs to be much higher. Whilst the Company is not necessarily forecasting an increase in the 1.8m active users, they believe there is a lot more to be derived from the current active user base with the new CEO very focused on
1. More personalised content and
2. Better valuation proposition across all services. Further, the Company is going to have more targeted/tailored discounted sales offering rather than broad base discounting impacting group gross margins.
Figure 2: GXL store network
Figure 3: GXL Financial Summary
Source: BTIG, Company, Bloomberg
Greencross Limited (GXL) is an Australasia leading specialist retailer of pet food, pet related products and pet accessories and also operates Australia’s largest veterinary services business. Key segments:
1. Retail – Greencross is Australasia’s leading specialty pet care retailer with over 230 stores, operating under the brand names of Petbarn and City Farmers in Australia and Animates in New Zealand.
2. Veterinary Services – Greencross owns and operates Australia’s largest network of veterinary practices with over 160 clinics including general practices, specialty and emergency centres, pathology labs and pet crematoria.
Recommendation Rating Guide
|Recommendation Rating Guide||Total Return Expectations on a 12-mth view|
|Speculative Buy||Greater than +30%|
|Buy||Greater than +10%|
|Neutral||Greater than 0%|
|Sell||Less than -10%|
Reach Markets Disclaimer
Reach Markets Pty Ltd (ABN 36 145 312 232) is a Corporate Authorised Representative of Reach Financial Group Pty Ltd (ABN 17 090 611 680) who holds Australian Financial Services Licence (AFSL) 333297. Please refer to our Financial Services Guide or you can request for a copy to be sent to you, by emailing firstname.lastname@example.org.
Read our full disclaimer here >
This publication contains general securities advice. In preparing the advice, Reach Markets Australia has not taken into account the investment objectives, financial situation and particular needs of any particular person. Before making an investment decision on the basis of this advice, you need to consider, with or without the assistance of a securities adviser, whether the advice in this publication is appropriate in light of your particular investment needs, objectives and financial situation. Reach Markets Australia and its associates within the meaning of the Corporations Act may hold securities in the companies referred to in this publication. Reach Markets Australia does, and seeks to do, business with companies that are the subject of its research reports. Reach Markets Australia believes that the advice and information herein is accurate and reliable, but no warranties of accuracy, reliability or completeness are given (except insofar as liability under any statute cannot be excluded). No responsibility for any errors or omissions or any negligence is accepted by Reach Markets Australia or any of its directors, employees or agents. This publication must not be distributed to retail investors outside of Australia.
It is recommended that you seek independent advice and read the relevant Product Disclosure Statement before making a decision in relation to any investment. Any advice contained in this communication is general and has not taken into account the investment objectives, financial situation and particular needs of any particular person.
Banyan Tree Disclaimer
This document is provided by Banyan Tree Investment Group (ACN 611 390 615; AFSL 486279) (“Banyan Tree”).
The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.
The material in this document has been obtained from sources believed to be true but neither Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy, or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and Banyan Tree is not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.
Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Banyan Tree does, and seeks to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.
Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Banyan Tree, its associates, officers, directors, employees and agents. Except for any liability which cannot be excluded, Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Banyan Tree is not liable to recipients in any matters whatsoever otherwise recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Banyan Tree does not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.
The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Banyan Tree.
This document has been commissioned by Reach Markets Australia Pty Ltd and provided by Banyan Tree Investment Group (ACN 611 390 615; AFSL 486279) (“Banyan Tree”).